Fidelity International’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.3M Sell
318,056
-1,488
-0.5% -$274K 0.05% 317
2025
Q4
$56.2M Buy
319,544
+11,547
+4% +$1.89M 0.04% 323
2025
Q3
$43.1M Buy
307,997
+63,665
+26% +$8.61M 0.03% 370
2025
Q2
$30.7M Buy
244,332
+124,332
+104% +$15.5M 0.03% 409
2025
Q1
$16.4M Buy
120,000
+15,283
+15% +$2.18M 0.02% 474
2024
Q4
$16M Sell
104,717
-91,285
-47% -$15.4M 0.02% 476
2024
Q3
$38M Sell
196,002
-594,603
-75% -$124M 0.03% 375
2024
Q2
$183M Buy
790,605
+88,193
+13% +$19.2M 0.18% 145
2024
Q1
$151M Buy
702,412
+45,910
+7% +$10.8M 0.15% 167
2023
Q4
$170M Buy
656,502
+593,158
+936% +$146M 0.18% 146
2023
Q3
$16.3M Sell
63,344
-642
-1% -$172K 0.02% 434
2023
Q2
$18.2M Buy
63,986
+99
+0.2% +$29.5K 0.02% 417
2023
Q1
$17.8M Buy
63,887
+8,864
+16% +$2.45M 0.02% 400
2022
Q4
$15.2M Buy
55,023
+2,747
+5% +$776K 0.02% 434
2022
Q3
$14M Buy
+52,276
New +$11.1M 0.02% 443
2022
Q2
Sell
-68,291
Closed -$14.4M 815
2022
Q1
$14.4M Sell
68,291
-4,375
-6% -$951K 0.01% 485
2021
Q4
$17.4M Sell
72,666
-1,734
-2% -$446K 0.02% 466
2021
Q3
$21.1M Sell
74,400
-2,403
-3% -$788K 0.02% 428
2021
Q2
$26.6M Sell
76,803
-17,034
-18% -$5.16M 0.03% 415
2021
Q1
$26.3M Buy
93,837
+14,157
+18% +$3.82M 0.03% 396
2020
Q4
$19.5M Buy
79,680
+78,580
+7,144% +$20.3M 0.02% 411
2020
Q3
$312K Buy
+1,100
New +$307K ﹤0.01% 671
2020
Q2
Sell
-37,802
Closed -$12M 873
2020
Q1
$12M Buy
37,802
+1,665
+5% +$505K 0.02% 424
2019
Q4
$10.7M Buy
+36,137
New +$10M 0.01% 496
2019
Q1
Sell
-201,969
Closed -$60.8M 860
2018
Q4
$60.8M Buy
201,969
+1,028
+0.5% +$328K 0.11% 202
2018
Q3
$71M Sell
200,941
-6,184
-3% -$2.13M 0.11% 207
2018
Q2
$60.1M Buy
207,125
+7,612
+4% +$2.14M 0.09% 234
2018
Q1
$54.6M Buy
199,513
+842
+0.4% +$261K 0.15% 148
2017
Q4
$63.3M Sell
198,671
-47,596
-19% -$15.3M 0.18% 139
2017
Q3
$77.1M Sell
246,267
-31,862
-11% -$9.43M 0.22% 112
2017
Q2
$75.5M Buy
278,129
+6,145
+2% +$1.62M 0.22% 118
2017
Q1
$74.4M Sell
271,984
-28,088
-9% -$7.94M 0.21% 120
2016
Q4
$85.1M Buy
300,072
+82,910
+38% +$24.6M 0.25% 105
2016
Q3
$68M Sell
217,162
-11,483
-5% -$3.4M 0.2% 117
2016
Q2
$55.3M Buy
228,645
+44,596
+24% +$11.8M 0.18% 126
2016
Q1
$47.9M Sell
184,049
-368
-0.2% -$97.2K 0.15% 144
2015
Q4
$56.5M Sell
184,417
-302,331
-62% -$86.9M 0.17% 130
2015
Q3
$142M Buy
486,748
+195,952
+67% +$64.7M 0.49% 61
2015
Q2
$117M Buy
290,796
+91,012
+46% +$36.5M 0.37% 78
2015
Q1
$84.4M Buy
199,784
+61,394
+44% +$24.2M 0.27% 98
2014
Q4
$47M Buy
138,390
+59,563
+76% +$19.3M 0.16% 143
2014
Q3
$26.1M Sell
78,827
-21,934
-22% -$7.23M 0.1% 199
2014
Q2
$31.8M Sell
100,761
-5,791
-5% -$1.74M 0.12% 174
2014
Q1
$32.6M Buy
106,552
+52,634
+98% +$16.7M 0.12% 180
2013
Q4
$15.1M Sell
53,918
-970
-2% -$251K 0.06% 277
2013
Q3
$13.2M Buy
54,888
+15,400
+39% +$3.45M 0.06% 268
2013
Q2
$8.5M Buy
+39,488
New +$8.44M 0.05% 301

Other funds holding BIIB

Fidelity International's BIIB Position: Q1 2026 in Review

Fidelity International reduced its Biogen (BIIB) stake by 0.47% in Q1 2026, selling an estimated $274K and leaving 318,056 shares worth $58.3M. The position accounts for 0.05% of the portfolio, ranked #317.

Fidelity International first reported a position in BIIB in Q2 2013 and has held it in 47 quarters since. The position peaked at $183M in Q2 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Fidelity International held 318,056 shares of Biogen worth $58.3M as of Q1 2026.
  • Fidelity International sold 1,488 Biogen shares in Q1 2026, an estimated $274K.
  • Biogen made up 0.05% of Fidelity International's portfolio in Q1 2026, its #317 holding.
  • Fidelity International first reported a position in Biogen in Q2 2013 and has held it in 47 quarters since.
  • Fidelity International's Biogen position peaked at $183M in Q2 2024.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.